Myositis can be difficult to treat. There are no standard treatment guidelines to follow, and the disease is heterogenous. Conventional treatment consists of steroids and an immunosuppressant such as Methotrexate, Azathioprine or Mycophenolate Mofetil. If patients continue to be symptomatic after an adequate trial of at least 3 months on therapeutic doses of these medications, this is considered refractory disease. Other treatment strategies that can be employed in this situation are discussed in this concise article. (Registration is Required)
Johns Hopkins Myositis Center
USE OF THIS SITE
All information contained within the Johns Hopkins Rheumatology website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.
